Table 1 Selected characteristics of patients with metastatic HR+/HER2- BC
Characteristic | Study cohort (N, %) | Treated with 1st LoT SACT (N, %) |
|---|---|---|
All patients | 196 | 185 |
Age at index date, median (range) | 67 years (33–92) | 68 years (33–92) |
< 55 years | 39 (19.9%) | 34 (18.4%) |
55–74 years | 99 (50.5%) | 97 (52.4%) |
75+ years | 58 (29.6%) | 54 (29.2%) |
Pre/peri-menopausala | 25 (12.8%) | 20 (10.8%) |
Post-menopausal | 167 (85.2%) | 161 (87.0%) |
Morphology (1° tumour) | ||
Infiltrating duct carcinoma, NOSb | 117 (59.7%) | 109 (58.9%) |
Lobular carcinoma, NOS | 29 (14.8%) | 28 (15.1%) |
Carcinoma, NOS | 26 (13.3%) | 26 (14.1%) |
Other | 24 (12.2%) | 22 (11.9%) |
Non-visceral metastasis onlyc | 73 (37.2%) | 66 (35.7%) |
Bone | 59 (30.1%) | 54 (29.2%) |
Lymph nodes | 24 (12.2%) | 21 (11.4%) |
Skin and soft tissue | 17 (8.7%) | 15 (8.1%) |
Non-visceral with visceral metastasisc | 88 (44.9%) | 86 (46.5%) |
Bone | 74 (37.8%) | 73 (39.5%) |
Lymph nodes | 44 (22.4%) | 42 (22.7%) |
Skin and soft tissue | 10 (5.1%) | 10 (5.4%) |
Pulmonary | 52 (26.5%) | 52 (28.1%) |
Liver | 40 (20.4%) | 39 (21.1%) |
Pleura | 26 (13.3%) | 25 (13.5%) |
Peritoneum | 10 (5.1%) | 9 (4.9%) |
CNS | 6 (3.1%) | 6 (3.2%) |
Visceral (incl. CNS) metastasis onlyc | 31 (15.8%) | 29 (15.7%) |
Pulmonary | 12 (6.1%) | 12 (6.5%) |
Liver | 16 (8.2%) | 14 (7.6%) |
Pleura | 7 (3.6%) | 7 (3.8%) |
CNS | < 6 | < 6 |
Metastatic status | ||
Recurrent metastatic | 124 (63.3%) | 111 (61.3%) |
De novo metastatic | 72 (36.7%) | 70 (38.7%) |